全文获取类型
收费全文 | 298971篇 |
免费 | 10469篇 |
国内免费 | 6196篇 |
专业分类
耳鼻咽喉 | 1759篇 |
儿科学 | 3776篇 |
妇产科学 | 3592篇 |
基础医学 | 17244篇 |
口腔科学 | 6168篇 |
临床医学 | 32545篇 |
内科学 | 32361篇 |
皮肤病学 | 2569篇 |
神经病学 | 11264篇 |
特种医学 | 16691篇 |
外国民族医学 | 4篇 |
外科学 | 34139篇 |
综合类 | 78433篇 |
一般理论 | 6篇 |
预防医学 | 34215篇 |
眼科学 | 4023篇 |
药学 | 15284篇 |
2篇 | |
中国医学 | 6912篇 |
肿瘤学 | 14649篇 |
出版年
2023年 | 293篇 |
2022年 | 546篇 |
2021年 | 881篇 |
2020年 | 1028篇 |
2019年 | 1041篇 |
2018年 | 1385篇 |
2017年 | 1025篇 |
2016年 | 1157篇 |
2015年 | 1373篇 |
2014年 | 1367篇 |
2013年 | 1399篇 |
2012年 | 2129篇 |
2011年 | 17788篇 |
2010年 | 9010篇 |
2009年 | 5470篇 |
2008年 | 15262篇 |
2007年 | 27915篇 |
2006年 | 27613篇 |
2005年 | 21488篇 |
2004年 | 22889篇 |
2003年 | 22850篇 |
2002年 | 19841篇 |
2001年 | 19028篇 |
2000年 | 14128篇 |
1999年 | 15109篇 |
1998年 | 8259篇 |
1997年 | 9394篇 |
1996年 | 9201篇 |
1995年 | 8570篇 |
1994年 | 7510篇 |
1993年 | 3946篇 |
1992年 | 3458篇 |
1991年 | 2784篇 |
1990年 | 2327篇 |
1989年 | 1674篇 |
1988年 | 1907篇 |
1987年 | 1070篇 |
1986年 | 867篇 |
1985年 | 575篇 |
1984年 | 168篇 |
1983年 | 95篇 |
1982年 | 77篇 |
1981年 | 83篇 |
1980年 | 72篇 |
1979年 | 77篇 |
1978年 | 72篇 |
1977年 | 53篇 |
1976年 | 62篇 |
1975年 | 49篇 |
1973年 | 60篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
1.
目的:探讨健脾益肾方对非小细胞肺癌(NSCLC)细胞体外增殖凋亡的作用。方法:人NSCLC细胞系A549分为四组:空白对照组(仅加入细胞培养液)、阴性对照组(加入细胞,不进行中药处理)、实验组(加细胞加中药处理)。荧光定量PCR和Western blot分别检测Survivin、Bcl-2和Caspase-3的mRNA和蛋白表达。MTT检测细胞增殖;流式细胞术检测细胞凋亡。结果:与空白对照组相比,阴性对照组细胞在24、48、72 h的吸光度值明显升高,细胞凋亡率下降,Survivin和Bcl-2 mRNA和蛋白相对表达量上调,Caspase-3 mRNA和蛋白相对表达量下调,组间比较差异有统计学意义(P<0.05);而健脾益肾方处理的实验组24、48、72 h的吸光度值均显著降低,细胞凋亡率显著上升,Survivin和Bcl-2 mRNA和蛋白相对表达量下调,Caspase-3 mRNA和蛋白相对表达量上调,与空白对照组相比差异有统计学意义(P<0.05)。结论:健脾益肾方可通过下调Survivin和Bcl-2、上调Caspase-3表达诱导NSCLC细胞凋亡,并抑制肿瘤细胞的增殖,进而抑制NSCLC的发展。 相似文献
2.
Cromb Amandine Le Loarer Franois Sitbon Maxime Italiano Antoine Stoeckle Eberhard Buy Xavier Kind Michle 《European radiology》2020,30(5):2413-2424
European Radiology - The strongest adverse prognostic factor in myxoid/round cell liposarcomas (MRC-LPS) is the presence of a round cell component above 5% within the tumor bulk. Its identification... 相似文献
3.
4.
5.
6.
7.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献
8.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献9.
Frédéric Janvier Deborah Delaune Thomas Poyot Eric Valade Audrey Mérens Pierre E. Rollin Vincent Foissaud 《Emerging infectious diseases》2016,22(2):292-294
We evaluated RNA stability of Ebola virus in EDTA blood and urine samples collected from infected patients and stored in West Africa’s environmental conditions. In blood, RNA was stable for at least 18 days when initial cycle threshold values were <30, but in urine, RNA degradation occurred more quickly. 相似文献